@curator

2 years ago

Article

AAN: AstraZeneca touts new Ultomiris gMG data ahead of potential Argenx showdown

Rating: 0.0

Likes: 1

Library: 1

AAN: AstraZeneca touts new Ultomiris gMG data ahead of potential Argenx showdown

When Argenx's Vyvgart won FDA approval in December for generalized myasthenia gravis (gMG), the entrant presented an attractive alternative to AstraZeneca's entrenched rare-disease blockbuster Soli | Tuesday at the American Academy of Neurology (AAN), AstraZeneca presented follow-up results from a phase 3 trial that enhance Ultomiris' chance for approval for generalized myasthenia gravis (gMG). With Soliris and Ultomiris, AZ is battling Argenx's newly approved Vyvgart in gMG.

Rate This Post

Rate The Educational Value

Rate The Ease of Understanding and Presentation

Interesting or Boring? Rate the Entertainment Value

AAN: AstraZeneca touts new Ultomiris gMG data ahead of potential Argenx showdown

Rate This Post

Related Topics

Comments

Media:

My Account:

Boostlane:

Select a Category

Topics Trending Today

Recommended Media

Boostlane Reward System

Unlocking the Power of Knowledge
for Humanity's Progress

Quick Links

Select a Locale

Unlocking the Power of Knowledge
for Humanity's Progress

AAN: AstraZeneca touts new Ultomiris gMG data ahead of potential Argenx showdown

Rate This Post

Related Topics

Comments

Media:

My Account:

Boostlane:

Select a Category

Topics Trending Today

Recommended Media

Boostlane Reward System

Unlocking the Power of Knowledge for Humanity's Progress

Quick Links

Select a Locale

Unlocking the Power of Knowledge for Humanity's Progress

Unlocking the Power of Knowledge
for Humanity's Progress

Unlocking the Power of Knowledge
for Humanity's Progress